Search research articles
Contact Us
Filters
Showing results (51-60 of 101) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2000
Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study
R Dreicer, J Manola, B J Roth, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1993
Evidence of an absorption phase after short intravenous suramin infusions
P R Hutson, K Tutsch, D Spriggs, et al.
Endocrine
|
November 3, 1998
Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques
H J Pan, G Wilding, H Uno, et al.
Cancer
|
October 15, 1993
Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group
B J Roth, B Y Yeap, G Wilding, et al.
International Journal of Oncology
|
November 20, 2001
Identification of the prostate cancer micro-foci with chromosome 8p deletion at the tumor interface area by histopathological-FISH parallel examination
S Q Wu, G R Hafez, J Zhang, et al.
Cancer Research
|
February 15, 1991
Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion
H Bailey, K D Tutsch, R Z Arzoomanian, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
A phase I study of 5-fluorouracil, leucovorin and levamisole
J F Cleary, R Arzoomanian, D Alberti, et al.
Investigational New Drugs
|
November 1, 1992
Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days
H Bailey, P Kohler, R Tuttle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1985
Retinal toxicity after high-dose cisplatin therapy
G Wilding, R Caruso, T S Lawrence, et al.
Investigational New Drugs
|
January 1, 1994
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma
J Berlin, A C King, K Tutsch, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 101) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2000
Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study
R Dreicer, J Manola, B J Roth, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1993
Evidence of an absorption phase after short intravenous suramin infusions
P R Hutson, K Tutsch, D Spriggs, et al.
Endocrine
|
November 3, 1998
Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques
H J Pan, G Wilding, H Uno, et al.
Cancer
|
October 15, 1993
Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group
B J Roth, B Y Yeap, G Wilding, et al.
International Journal of Oncology
|
November 20, 2001
Identification of the prostate cancer micro-foci with chromosome 8p deletion at the tumor interface area by histopathological-FISH parallel examination
S Q Wu, G R Hafez, J Zhang, et al.
Cancer Research
|
February 15, 1991
Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion
H Bailey, K D Tutsch, R Z Arzoomanian, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
A phase I study of 5-fluorouracil, leucovorin and levamisole
J F Cleary, R Arzoomanian, D Alberti, et al.
Investigational New Drugs
|
November 1, 1992
Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days
H Bailey, P Kohler, R Tuttle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1985
Retinal toxicity after high-dose cisplatin therapy
G Wilding, R Caruso, T S Lawrence, et al.
Investigational New Drugs
|
January 1, 1994
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma
J Berlin, A C King, K Tutsch, et al.
Page
of 11